CoChat
Cited by 186

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline

Open access
Trabulsi, Edouard J., Rumble, R. Bryan, Jadvar, Hossein, Hope, Thomas, Pomper, Martin, Turkbey, Baris, Rosenkrantz, Andrew B., Verma, Sadhna, Margolis, Daniel J., Froemming, Adam, Oto, Aytekin, Purysko, Andrei, Milowsky, Matthew I., Schlemmer, Heinz-Peter, Eiber, Matthias, Morris, Michael J., Choyke, Peter L., Padhani, Anwar, Oldan, Jorge, Fanti, Stefano, Jain, Suneil, Pinto, Peter A., Keegan, Kirk A., Porter, Christopher R., Coleman, Jonathan A., Bauman, Glenn S., Jani, Ashesh B., Kamradt, Jeffrey M., Sholes, Westley, Vargas, H. Alberto · 2020 · Journal of Clinical Oncology

Abstract

PURPOSE: Provide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups. METHODS: An Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naïve metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared ≥ 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality. RESULTS: A total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles. RECOMMENDATIONS: One or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.02757

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

Metadata

Authors
Trabulsi, E. J., Rumble, R. B., Jadvar, H., Hope, T., Pomper, M., Turkbey, B., Rosenkrantz, A. B., Verma, S., Margolis, D. J., Froemming, A., Oto, A., Purysko, A., Milowsky, M. I., Schlemmer, H.-P., Eiber, M., Morris, M. J., Choyke, P. L., Padhani, A., Oldan, J., Fanti, S., Jain, S., Pinto, P. A., Keegan, K. A., Porter, C. R., Coleman, J. A., Bauman, G. S., Jani, A. B., Kamradt, J. M., Sholes, W., & Vargas, H. A.
Venue
Journal of Clinical Oncology
Published
2020-06-10
Volume
38
Issue
17
Pages
1963-1996
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3000715936
Cited by
186
References
6
FWCI
13.79
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.